Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia

NCT04289207 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT04289207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04289207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia
Lead sponsor
Seoul National University Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
March 1, 2020
Completion date
March 1, 2021
Enrollment
55 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia